Xilio Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Xilio Therapeutics, Inc. (XLO) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $30.20 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-08-12
- 2026-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $30.20M.
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $26.26M.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $29.56M.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $53.93M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2026-06-30 | $30.20M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $26.26M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $29.56M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $53.93M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $38.55M 10-Q · filed 2025-08-14 |
| 2021-09-30 | $1.27M 10-Q · filed 2021-12-02 |
| 2020-12-31 | $825.00K 10-K · filed 2023-03-02 |
| 2019-12-31 | $374.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |